VD1-6

VD1-6 is a novel C-24 O-methyloxime analogue of vitamin D3 designed as a specific inhibitor of Cytochrome P450 24-hydroxylase (CYP24A1). CYP24A1 is the primary enzyme responsible for the catabolism of active vitamin D (1,25(OH)2D3) and its precursor (25(OH)D3). In conditions such as chronic kidney disease (CKD), the upregulation of CYP24A1 contributes to vitamin D deficiency, which in turn drives secondary hyperparathyroidism (SHPT), bone deterioration, and cardiovascular calcification. Unlike traditional vitamin D analogues, VD1-6 does not bind to the vitamin D receptor (VDR) at therapeutic concentrations, thereby avoiding direct VDR-mediated side effects. Instead, it functions by potentiating endogenous vitamin D activity through the inhibition of its degradation pathway. VD1-6 has demonstrated superior in silico binding to CYP24A1 compared to calcitriol and has shown efficacy in reducing the accumulation of catabolic metabolites in vitro, making it a potential therapeutic candidate for SHPT.

Other names

C-24 O-methyloxime analogue of vitamin D3C24 O-methyloxime analogue of vitamin D3C 24 O-methyloxime analogue of vitamin D3C-24 O-methyloxime vitamin D3 analogueC24 O-methyloxime vitamin D3 analogueC 24 O-methyloxime vitamin D3 analogue